echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Study on the risk of adverse events of myocarditis after mass vaccination of BNT162b2 vaccine in Israel

    NEJM: Study on the risk of adverse events of myocarditis after mass vaccination of BNT162b2 vaccine in Israel

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BNT162b2 mRNA vaccine is the world's first large-scale use of the new crown pneumonia mRNA vaccines, 2020 December 20, Israel launched a nationwide vaccination campaign, more than 16 years of age received two doses of vaccine regimen 21 days apart


    The new crown pneumonia after researchers recently vaccinated BNT162b2 mRNA vaccine has been systematically studied the risk of myocarditis myocarditis risk after researchers recently vaccinated BNT162b2 mRNA vaccine has been systematically studied

    The researchers reviewed the data of all myocarditis cases in Israel from December 20, 2020 to May 31, 2021, examined the incidence of myocarditis after the first and second vaccination (21 days apart), and calculated after the first administration The incidence of myocarditis observed at 21 days and 30 days after the second dose was compared with historical data over the same period and data from the unvaccinated population


    During the study period, 304 patients with myocarditis symptoms were reported, of which 21 were diagnosed with other diseases.


    Diagnosis Compared with the expected incidence based on historical data, the standardized incidence of myocarditis after vaccination in 16-19-year-old males was 5.


    Myocarditis after BNT162b2 vaccination

    Myocarditis event after BNT162b2 vaccination BNT162b2 myocarditis event after vaccination

    The study found that vaccination with BNT162b2 vaccine has a lower absolute risk of adverse events of myocarditis, but the risk of myocarditis after vaccination in young men is worthy of attention.


    Vaccination of BNT162b2 vaccine, the absolute risk of adverse events of myocarditis is low, but the risk of myocarditis after vaccination in young men is worthy of attention.


    Original source:

    Dror Mevorach et al.


    Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.